CKD cases surge to 16.38% in Indians aged 15+
Experts urge early detection & better access to care
Experts urge early detection & better access to care
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated